Vaxart, Inc.
170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com
版塊: Healthcare
行業: Biotechnology
全職員工: 109
描述
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
公司管治
截至 2024年6月1日 止，Vaxart, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：7；股東權利：6；現金賠償：9。
